These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25773385)

  • 1. Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.
    Zhou J; Qian S; Li H; He W; Tan X; Zhang Q; Han G; Chen G; Luo R
    Tumour Biol; 2015 May; 36(5):3941-7. PubMed ID: 25773385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy.
    Li ZH; Xiong QY; Tu JH; Gong Y; Qiu W; Zhang HQ; Wei WS; Hou YF; Cui WQ
    Med Oncol; 2013; 30(3):591. PubMed ID: 23681778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and Prognostic Value of the TauProtein in Breast Cancer.
    Bonneau C; Gurard-Levin ZA; Andre F; Pusztai L; Rouzier R
    Anticancer Res; 2015 Oct; 35(10):5179-84. PubMed ID: 26408675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
    Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
    J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer.
    Yang L; Yang S; Liu J; Wang X; Ji J; Cao Y; Lu K; Wang J; Gao Y
    Exp Mol Pathol; 2014 Apr; 96(2):235-41. PubMed ID: 24602846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
    Kilic E; Milde-Langosch K; Müller V; Wirtz R; Ihnen M
    Pathologe; 2008 Nov; 29 Suppl 2():347-52. PubMed ID: 18810438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
    Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
    Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
    Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
    Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
    Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
    BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
    Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
    Dai K; Qin F; Zhang H; Liu X; Guo C; Zhang M; Gu F; Fu L; Ma Y
    Oncotarget; 2016 Jan; 7(4):4770-84. PubMed ID: 26684357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer.
    Honig A; Gehrmann M; Kranke P; Keller D; Engel JB; Hengstler S; Schmidt M
    Eur J Gynaecol Oncol; 2014; 35(5):503-7. PubMed ID: 25423693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stratification with respect to hormone receptor and HER 2/neu in the treatment of metastatic breast cancer; sensitivity to taxane].
    Kan N; Mise K; Moriguchi Y; Kodama H
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):53-7. PubMed ID: 17220670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.